Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | TYK2 | P29597 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 2/20 | 0.41 |
| ▸ | CCND3 | P30281 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4506484 | 0.89 | AURKA (0.54) | AURKAAURKBCDK2JAK2JAK1 | |
| SCHEMBL4497885 | 0.89 | AURKA (0.47) | AURKAAURKBGUSBMEN1MAPT | |
| SCHEMBL4497883 | 0.89 | AURKA (0.47) | AURKAAURKBGUSBMEN1MAPT | |
| SCHEMBL4506681 | 0.87 | AURKA (0.50) | AURKAAURKBCDK2JAK2JAK1 | |
| SCHEMBL4510663 | 0.86 | AURKA (0.51) | AURKAAURKBCDK2JAK2JAK1 | |
| SCHEMBL5189691 | 0.86 | AURKA (0.54) | AURKAAURKBMEN1MAPTHTT | |
| SCHEMBL4508446 | 0.85 | CHEK1 (0.53) | AURKAAURKBCDK2JAK2JAK1 | |
| SCHEMBL4504819 | 0.85 | AURKA (0.52) | AURKAAURKBCDK2JAK2JAK1 | |
| SCHEMBL4505475 | 0.84 | AURKA (0.54) | AURKAAURKBCDK2JAK2JAK1 | |
| SCHEMBL4517359 | 0.84 | AURKA (0.51) | AURKAAURKBCDK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | claimed |
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | GEORGES GUY | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291968-A1 | SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | CYP3A43, CYP3A5, CYP3A7 | AURKA 1558/4885AURKB 2087/4885GUSB 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.